Cargando…
Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients—A BioCAPTURE Registry Study
BACKGROUND: Psoriasis is a common inflammatory disease in any age group, but also in older patients (≥ 65 years of age). Since older patients are often excluded from clinical trials, limited data specifically on this growing population are available, e.g. regarding the safety and performance of biol...
Autores principales: | ter Haar, E. L. M., Thomas, S. E., van den Reek, J. M. P. A., Otero, M. E., Njoo, M. D., Ossenkoppele, P. M., Kop, E. N., Dodemont, S. R. P., Körver, J. E. M., Kuijpers, A. L. A., Lindhout, R. J., Tupker, R. A., Mommers, J. M., Berends, M. A. M., Koetsier, M. I. A., de Bruin-Weller, M. S., Visch, M. B., Arnold, W. P., van Lümig, P. P. M., Kleinpenning, M. M., Lubeek, S. F. K., de Jong, E. M. G. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300332/ https://www.ncbi.nlm.nih.gov/pubmed/35859228 http://dx.doi.org/10.1007/s40266-022-00961-y |
Ejemplares similares
-
Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort
por: VAN MUIJEN, Marloes. E., et al.
Publicado: (2022) -
Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study
por: ATALAY, Selma, et al.
Publicado: (2020) -
Safety Assessment of Conventional and Biological Systemic Therapy in Older Adults with Psoriasis, a Real-world Multicentre Cohort Study
por: TER HAAR, Elke L. M., et al.
Publicado: (2022) -
Biopsy outperforms reflectance confocal microscopy in diagnosing and subtyping basal cell carcinoma: results and experiences from a randomized controlled multicentre trial
por: Woliner–van der Weg, W., et al.
Publicado: (2020) -
Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks
por: TER HAAR, Elke L. M., et al.
Publicado: (2023)